Developing In Vitro–In Vivo Correlation of Risperidone Immediate Release Tablet
- 14 June 2012
- journal article
- Published by Springer Science and Business Media LLC in AAPS PharmSciTech
- Vol. 13 (3), 890-895
- https://doi.org/10.1208/s12249-012-9814-3
Abstract
The present study was aimed to predict the absorption profile of a risperidone immediate release tablet (IR) and to develop the level A in vitro–in vivo correlation (IVIVC) of the drug using the gastrointestinal simulation based on the advanced compartmental absorption and transit model implemented in GastroPlus™. Plasma concentration data, physicochemical, and pharmacokinetic properties of the drug were used in building its absorption profile in the gastrointestinal tract. Since the fraction absorbed of risperidone in simulation was more than 90% with low water solubility, the drug met the criteria of class II of the Biopharmaceutics Classification System. The IVIVC was developed based on the model built using the plasma data and the in vitro dissolution data in several dissolution media based on the Japanese Guideline for Bioequivalence Studies of Generic Products. The gastrointestinal absorption profile of risperidone was successfully predicted. A level A IVIVC was also successfully developed in all dissolution media with percent prediction error for Cmax and the area under the curve less than 10% for both reference and test drug.Keywords
This publication has 16 references indexed in Scilit:
- Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteersClinical Therapeutics, 2010
- Computer simulations using GastroPlus™ to justify a biowaiver for etoricoxib solid oral drug productsEuropean Journal of Pharmaceutics and Biopharmaceutics, 2009
- Dynamic Dissolution Testing To Establish In Vitro/In Vivo Correlations for Montelukast Sodium, a Poorly Soluble DrugPharmaceutical Research, 2008
- A Provisional Biopharmaceutical Classification of the Top 200 Oral Drug Products in the United States, Great Britain, Spain, and JapanMolecular Pharmaceutics, 2006
- Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophreniaActa Pharmacologica Sinica, 2006
- A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptorsInternational Clinical Psychopharmacology, 1995
- RisperidoneDrugs, 1994
- Plasma protein binding of risperidone and its distribution in bloodPsychopharmacology, 1994
- Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjectsClinical Pharmacology & Therapeutics, 1993
- Processes of absorption, distribution, and excretionPublished by Royal Society of Chemistry (RSC) ,1970